/
Oncology
Urinary Bladder Neoplasms
12
Pipeline Programs↗
13
Active Trials↗
12
Companies Involved↗
Urinary Bladder Neoplasms is an emerging landscape with 12 programs across 12 companies. The most active players are Eli Lilly. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 18
Phase 31
Approved
No programs
Analysis
Modality Breakdown
11programs
Small molecule655%
Monoclonal antibody327%
Antibody–drug conjugate218%
Modality classified for 92% of 12 pipeline programs.
Analysis
Trial Status
20
clinical trials
Recruiting6 · 30%
Completed5 · 25%
Active, not recruiting4 · 20%
Not yet recruiting3 · 15%
Terminated1 · 5%
Available1 · 5%
Clinical Trials
Trial Activity
20 trials
Toripalimab With Sequential Intravesical Gemcitabine-Mitomycin C Versus Toripalimab Alone for the Treatment of BCG-Unresponsive/-Intolerant High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized, Multicenter, Phase 2 Study
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07189793·106 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)